Cisco, Microsoft and Citi all returned to lift cybersecurity technology provider Illusive Networks' total funding to $54m.

Intel Capital led the cybersecurity software developer's series A round, which boosted its overall funding to $20m.

The Tencent-backed social gaming platform developer had been reported to be targeting an $8bn valuation in its initial public offering.

Novo and Roche are in line for exits from hepatitis drug developer Aligos Therapeutics, which has raised some $230m since it was founded in 2018.

GV, Orient Life and Illumina Ventures are in line to exit cell therapy and vaccine developer SQZ Biotechnologies, which has filed for a $75m offering.

The Omron-backed disease prevention platform developer hiked its total debt and equity financing to $100m, King River Capital leading the series C.

Recruit Strategic Partners has exited the identity management platform developer in a purchase by Ping Identity.

The $10m investment fund formed by the electronic components manufacturer and its Taiyo America subsidiary will target developers of technologies and products related to its core business.

MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.